chr5-138824559-G-C
Variant summary
Our verdict is Benign. The variant received -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_001903.5(CTNNA1):c.618G>C(p.Gln206His) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00441 in 1,614,158 control chromosomes in the GnomAD database, including 38 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Q206L) has been classified as Uncertain significance.
Frequency
Consequence
NM_001903.5 missense
Scores
Clinical Significance
Conservation
Publications
- CTNNA1-related diffuse gastric and lobular breast cancer syndromeInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- patterned macular dystrophy 2Inheritance: AD Classification: DEFINITIVE, STRONG, LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics
- patterned macular dystrophyInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary nonpolyposis colon cancerInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -20 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| CTNNA1 | NM_001903.5 | c.618G>C | p.Gln206His | missense_variant | Exon 6 of 18 | ENST00000302763.12 | NP_001894.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| CTNNA1 | ENST00000302763.12 | c.618G>C | p.Gln206His | missense_variant | Exon 6 of 18 | 1 | NM_001903.5 | ENSP00000304669.7 |
Frequencies
GnomAD3 genomes AF: 0.00397 AC: 605AN: 152202Hom.: 5 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.00462 AC: 1160AN: 251306 AF XY: 0.00439 show subpopulations
GnomAD4 exome AF: 0.00445 AC: 6508AN: 1461840Hom.: 33 Cov.: 31 AF XY: 0.00439 AC XY: 3192AN XY: 727218 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00397 AC: 605AN: 152318Hom.: 5 Cov.: 32 AF XY: 0.00397 AC XY: 296AN XY: 74480 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Benign:4
This variant is associated with the following publications: (PMID: 11997091, 29177109)
The CTNNA1 p.Gln206His variant was identified in 1 of 572 proband chromosomes (frequency: 0.00175) from European families with diffuse gastric cancer (Weren_2018_PMID:29330337). The variant was identified in dbSNP (ID: rs150893072), ClinVar (classified as benign by Invitae), and LOVD 3.0. The variant was also identified in control databases in 1298 of 282710 chromosomes (13 homozygous) at a frequency of 0.004591 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: European (Finnish) in 448 of 25122 chromosomes (freq: 0.01783), Other in 44 of 7224 chromosomes (freq: 0.006091), European (non-Finnish) in 723 of 129042 chromosomes (freq: 0.005603), Latino in 59 of 35424 chromosomes (freq: 0.001666), African in 23 of 24968 chromosomes (freq: 0.000921), South Asian in 1 of 30612 chromosomes (freq: 0.000033), while the variant was not observed in the Ashkenazi Jewish or East Asian populations. The p.Gln206 residue is conserved in mammals but not in more distantly related organisms, however four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and two of four in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign.
CTNNA1: BS2
not specified Benign:1
Hereditary diffuse gastric adenocarcinoma Benign:1
This variant is considered benign. Homozygosity has been confirmed in one or more individuals. As homozygosity for pathogenic variants in this gene is generally assumed to result in embryonic lethality, this variant is unlikely to be pathogenic. This variant has been observed at a population frequency that is significantly greater than expected given the associated disease prevalence and penetrance.
CTNNA1-related disorder Benign:1
This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).
Hereditary cancer-predisposing syndrome Benign:1
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
Patterned macular dystrophy 2 Benign:1
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at